Pharmacokinetics and Pharmacodynamics of Anticoagulants in Paediatric Patients
Authors:
- 25 June 2013
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 52 (11) , 967-980
Abstract
Given the rising incidence of thrombotic complications in paediatric patients, understanding of the pharmacologic behaviour of anticoagulant drugs in children has gained importance. Significant developmental differences between children and adults in the haemostatic system and pharmacologic parameters for individual drugs highlight potentially unique aspects of anticoagulant pharmacology in this special and vulnerable population. This review focuses on pharmacologic information relevant to the dosing of unfractionated heparin, low molecular weight heparin, warfarin, bivalirudin, argatroban and fondaparinux in paediatric patients. The bulk of clinical experience with paediatric anticoagulation rests with the first three of these agents, each of which requires higher bodyweight-based dosing for the youngest patients, compared with adults, in order to achieve comparable pharmacodynamic effects, likely related to an inverse correlation between age and bodyweight-normalized clearance of these drugs. Whether extrapolation of therapeutic ranges targeted for adult patients prescribed these agents is valid for children, however, is unknown and a high priority for future research. Novel oral anticoagulants, such as dabigatran, rivaroxaban and apixaban, hold promise for future use in paediatrics but require further pharmacologic study in infants, children and adolescents.Keywords
This publication has 105 references indexed in Scilit:
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirementBlood, 2012
- Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in childrenJournal of Thrombosis and Haemostasis, 2011
- Age‐specific differences in binding of heparin to plasma proteinsJournal of Thrombosis and Haemostasis, 2010
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenBritish Journal of Pharmacology, 2008
- Incidence of venous thromboembolism in infants and children: Data from the National Hospital Discharge SurveyThe Journal of Pediatrics, 2004
- Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding studyThe Journal of Pediatrics, 1996
- Anticoagulation with sodium warfarin in children: Effect of a loading regimenThe Journal of Pediatrics, 1988